News
Pano Therapeutics provided an update on PAN1195, its CNS-optimized biguanide for Fragile X Syndrome, outlining a biomarker-led path toward early clinical development and planned expansion across related neurodevelopmental disorders.
Pano Therapeutics expanded its scientific and clinical advisory network supporting PAN1195, its CNS-optimized biguanide for Fragile X Syndrome, adding expertise across mechanistic pharmacology, clinical development and biomarker strategy, and regulatory science.
Dr. Ring, former Chief Executive Officer of Kaerus Bioscience, former Chief Scientific Officer of Autism Speaks, and former Head of Autism Research at Pfizer, joins Pano Therapeutics’ Scientific Advisory Board as Lead Neurodevelopmental Disorder Advisor to support scientific strategy, business development, and partnering as the company advances PAN1195 toward clinical development in Fragile X Syndrome.